**Key Takeaways:**

• **Rapid Fund Growth in a Tough Market:** Dimension Capital, founded in late 2022, has defied a challenging VC landscape by rapidly raising increasingly larger funds, culminating in an $800 million third vehicle, a 60% increase from its previous fund just 18 months prior.
• **Prescient Deep-Tech Thesis:** The firm’s founders — Zavian Dar, Adam Goulburn (ex-Lux Capital), and Nan Li (ex-Obvious Ventures) — bet on the convergence of biotech and software, a “science and compute” thesis that has played out remarkably quickly, validating their early vision.
• **High-Impact Portfolio:** Dimension’s portfolio showcases its strategic investments in high-growth deep-tech companies like Chai Discovery ($3.8B valuation) and anti-aging startup New Limit ($3.1B valuation), alongside strategic exits like Coefficient Bio’s acquisition by AI giant Anthropic.

Dimension Capital Defies VC Downturn with $800 Million Fund for Deep-Tech Frontier

In a venture capital landscape still grappling with a funding winter, one firm is not just surviving but thriving, rapidly scaling its capital commitments to the cutting edge of innovation. Dimension Capital, the New York-based firm established in late 2022, has once again shattered expectations, announcing an impressive new $800 million fund. This latest vehicle marks a significant 60% increase over its $500 million second fund, which itself was unveiled just 18 months ago, cementing Dimension’s position as a formidable player at the intersection of science and compute.

The firm’s meteoric rise is particularly striking given the broader market conditions, where many newer VC firms struggle to secure fresh capital. Dimension’s success is a testament to its prescient investment thesis and the collective expertise of its founding partners. Zavian Dar and Adam Goulburn, both formerly partners at the renowned Lux Capital, teamed up with Nan Li, an alum of Obvious Ventures, to launch Dimension. Their foundational bet, made just a few years ago, was that the next generation of groundbreaking companies would increasingly emerge from the convergence of deep-tech, specifically bridging the boundaries of biotech and advanced software. Today, the three partners admit their thesis has not only played out but has done so with remarkable speed and impact.

The Architects of a New Frontier: A Visionary Founding Team

The synergy among Dimension Capital’s founders is a cornerstone of its success. Zavian Dar and Adam Goulburn bring a wealth of experience from Lux Capital, a firm celebrated for its early and often contrarian bets on emerging science and technology. Their tenure at Lux instilled a deep appreciation for the long-term potential of complex, capital-intensive ventures at the frontier of discovery. Nan Li, from his background at Obvious Ventures, complements this perspective with an understanding of impact-driven innovation and the operational nuances required to scale transformative companies.

Together, they forged Dimension Capital with a clear, focused mandate: to back founders building companies that intrinsically link scientific breakthroughs with computational power. This “science and compute” thesis isn’t merely a buzzword; it reflects a fundamental shift in how innovation happens. From accelerating drug discovery with AI to engineering new materials and combating aging through biological programming, the firm identifies opportunities where software isn’t just a tool, but an integral component of scientific progress, enabling faster iteration, deeper insights, and unprecedented scale. This holistic approach has allowed Dimension to consistently identify and invest in companies poised to redefine their respective industries, even when the broader market remains cautious.

Portfolio Powerhouses: Exemplifying the Thesis in Action

Dimension Capital’s portfolio stands as a vivid illustration of its investment philosophy. A standout example is Chai Discovery, where Dimension co-led a $30 million seed investment in 2024. Chai, focused on developing open-source AI foundation models for drug development, recently made headlines with a staggering $400 million raise at a $3.8 billion valuation. This rapid appreciation underscores the immense market demand for AI-driven solutions to accelerate the notoriously slow and expensive process of pharmaceutical innovation. Dimension’s early backing of Chai demonstrates its ability to identify companies that are not just leveraging AI, but fundamentally rethinking industry paradigms.

Another significant investment is New Limit, the ambitious anti-aging startup co-founded by Coinbase CEO Brian Armstrong. Dimension backed New Limit at its Series A round in January 2025. Just earlier this month, New Limit completed a Series C funding round, securing a $3.1 billion valuation. The longevity and anti-aging sector, while nascent, holds immense promise and attracts visionary entrepreneurs and investors. Dimension’s involvement highlights its willingness to support high-risk, high-reward ventures that could fundamentally alter human health and lifespan, demonstrating conviction in the long-term impact of deep science.

The firm’s strategic acumen is further evidenced by its involvement with inference company Modal Labs, which plays a crucial role in providing scalable, on-demand compute infrastructure for AI applications. Perhaps one of the most compelling validations of Dimension’s thesis came with its portfolio company, Coefficient Bio. The drug discovery platform was acquired this spring by AI giant Anthropic for a reported $400 million. As a result of this acquisition, Dimension received shares in Anthropic, marking a significant return and a powerful testament to the value of integrating biological insights with advanced computational models. This strategic exit not only provided a strong financial return but also demonstrated how Dimension’s deep-tech bets can lead to critical components for the broader AI ecosystem.

Navigating a Challenging Landscape with Conviction

Dimension Capital’s ability to consistently raise larger funds in quick succession during a period of widespread VC retrenchment is remarkable. While many firms struggle with limited partners tightening their purses, Dimension’s clear strategy, proven track record, and a pipeline of high-potential companies have resonated strongly. This success points to a growing recognition among LPs that while broader tech investments may be cooling, the deep-tech sector — particularly at the nexus of science and compute — represents an indispensable frontier for long-term growth and societal impact. Dimension’s founders have not only identified this macro trend but have also built an operational model that allows them to identify, nurture, and accelerate companies that are poised to capitalize on it.

The firm’s focus isn’t just on writing checks; it’s about providing strategic guidance, leveraging their extensive networks, and offering deep industry insights to their portfolio companies. This hands-on approach, combined with a willingness to invest in complex, capital-intensive problems that others might shy away from, has cultivated a reputation for being a value-add partner to founders pushing the boundaries of what’s possible. Their rapid fundraising is not just about capital; it’s about the trust and belief the market places in their vision and execution.

**Bottom Line:** Dimension Capital’s swift rise and successive, larger fund closes, culminating in its new $800 million vehicle, underscore a powerful and increasingly validated investment thesis: the future of innovation lies at the complex intersection of science and compute. By backing visionary founders tackling ambitious challenges in biotech and software, the firm has not only defied a challenging venture capital market but has also positioned itself as a key architect in shaping the next generation of deep-tech powerhouses, promising significant returns and transformative advancements across industries.